Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Angela Hwang is a member of Pfizer’s Executive Team and Group President of the Pfizer Biopharmaceuticals Group, which comprises 80% of Pfizer’s revenues. Her organization of 26,000 colleagues is responsible for bringing over 600 innovative medicines and products to patients. As Group President of Pfizer Biopharma, Angela leads 7 commercial business units, reaching patients in more than 125 countries. Together, these businesses strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines.
Angela has been with Pfizer for 23 years, working across all geographies and therapeutic areas. She is motivated by the common purpose that all Pfizer colleagues share, to bring breakthroughs to patients, regardless of where they are in the world. Her childhood as an Asian girl growing up in apartheid South Africa, defined her worldview and underscored the importance of equity in everything she does today.
In addition to UPS, Angela sits on the boards of EFPIA (European Federation of Pharmaceutical Industries and Associations), as well as the Pfizer Foundation, a charitable organization that addresses global health challenges. She has also been active in industry groups such as BIO, where she previously co-chaired the Vaccines Policy Committee. In 2019, she was named in Crain’s Notable Women in Healthcare list.
Having always been curious about transformation and the art of the possible, in 2019, Angela launched Diverse Perspectives, a podcast series where she hosts global thought leaders pioneering change across a variety of industries.
Angela joined the UPS Board of Directors in 2020, and serves on the Audit Committee.
Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and MBA from Cornell University, and is a strong advocate for women’s leadership and sustainable global health equity.
